Join our team in transforming the cancer care!
We are looking for a proactive and analytical person to join Faron as Central Laboratory Manager. The main focus of this position is to work closely with Faron’s Scientific Lead, Clinical Operations in the coordination of all activities related to central laboratory services for clinical trials and work closely with sponsors and CROs to ensure study protocols are adhered to throughout the process. This position offers an exciting opportunity to work today with tomorrow’s breakthroughs. The Central Laboratory Manager will be reporting to VP, Operations.
Key responsibilities
Desirable Background and Expertise
Why Faron?
At Faron, your work is a meaningful part in our mission to transform cancer care. Finding the right person with a passionate and professional attitude to enhance our talented team is a priority for us. We value the willingness to develop processes and face new situations and challenges directly. To support this, we offer good opportunities to develop your own professional skills through a range of training courses.
With us you can be part of dynamic working environment with a culture of collaboration and open communication. We are based in Turku, Finland, but this role allows you to work remotely in either the UK or one of the EU countries (work visa in this region). Please note, however, that some travel may be required as part of this role.
Interested and confident you could be the person we are looking for? Please apply via link and attach CV in English including your salary expectation. We hope to hear from you as soon as possible but no later than 15th January, 2025 .
For any further questions or support with submitting your application, please contact us at [email protected].
Faron is a clinical stage biopharmaceutical company focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. The company was founded in 2007 in Turku, Finland.
Find out more about Faron at www.faron.com .